Studies of microbiota reveal inter-relationships between the microbiomes of the gut and lungs. This relationship may influence the progression of lung disease, particularly in patients with cystic fibrosis (CF), who often experience extraoesophageal reflux (EOR). Despite identifying this relationship, it is not well characterised. Our hypothesis is that the gastric and lung microbiomes in CF are related, with the potential for aerodigestive pathophysiology. We evaluated gastric and sputum bacterial communities by culture and 16S rRNA gene sequencing in 13 CF patients. Impacts of varying levels of bile acids, pepsin and pH on patient isolates of Pseudomonas aeruginosa (Pa) were evaluated. Clonally related strains of Pa and NTM were identified in gastric and sputum samples from patients with symptoms of EOR. Bacterial diversity was more pronounced in sputa compared to gastric juice. Gastric and lung bile and pepsin levels were associated with Pa biofilm formation. Analysis of the aerodigestive microbiomes of CF patients with negative sputa indicates that the gut can be a reservoir of Pa and NTM. This combined with the CF patient's symptoms of reflux and potential aspiration, highlights the possibility of communication between microorganisms of the gut and the lungs. This phenomenon merits further research.
Cystic Fibrosis , Gastroesophageal Reflux , Microbiota , Bacteria , Bile , Cystic Fibrosis/microbiology , Gastric Juice/microbiology , Gastroesophageal Reflux/complications , Humans , Lung/microbiology , Microbiota/genetics , Pepsin A , Pseudomonas aeruginosa/genetics , RNA, Ribosomal, 16S/genetics , Sputum/microbiology
After MDT work-up and review, gastro-oesophageal reflux and pulmonary aspiration were found to be common in IPF patients; surgery was recommended in only 10% http://ow.ly/rO3T30lU17o.
BACKGROUND: Extra-oesophageal reflux (EOR) may lead to microaspiration in patients with cystic fibrosis (CF), a probable cause of deteriorating lung function. Successful clinical trials of ivacaftor highlight opportunities to understand EOR in a real world study. METHODS: Data from 12 patients with CF and the G551D mutation prescribed ivacaftor (150mg bd) was collected at baseline, 6, 26 and 52weeks. The changes in symptoms of EOR were assessed by questionnaire (reflux symptom index (RSI) and Hull airway reflux questionnaire (HARQ)). RESULTS: Six patients presented EOR at baseline (RSI >13; median 13; range 2-29) and 5 presented airway reflux (HARQ >13; median 12; range 3 to 33). Treatment with ivacaftor was associated with a significant reduction of EOR symptoms (P<0â04 versus baseline) denoted by the reflux symptom index and Hull airway reflux questionnaire. CONCLUSION: Ivacaftor treatment was beneficial for patients with symptoms of EOR, thought to be a precursor to microaspiration.
Aminophenols/administration & dosage , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis , Gastroesophageal Reflux , Lung/physiopathology , Quinolones/administration & dosage , Respiratory Aspiration , Adult , Chloride Channel Agonists/administration & dosage , Cystic Fibrosis/diagnosis , Cystic Fibrosis/drug therapy , Cystic Fibrosis/genetics , Cystic Fibrosis/physiopathology , Drug Monitoring/methods , Female , Gastroesophageal Reflux/complications , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/physiopathology , Humans , Male , Mutation , Respiratory Aspiration/diagnosis , Respiratory Aspiration/etiology , Respiratory Aspiration/physiopathology , Respiratory Aspiration/prevention & control , Respiratory Function Tests/methods , Treatment Outcome , United Kingdom/epidemiology
